Singapoo - Kiingereza - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - entecavir - tablet, film coated - 0.5 mg - entecavir 0.5 mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - entecavir - tablet, film coated - 1 mg - entecavir 1 mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - peginterferon alfa-2a - injection - 135 mcg/0.5 ml - peginterferon alfa-2a 135 mcg/0.5 ml

Singapoo - Kiingereza - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - peginterferon alfa-2a - injection - 180 mcg/0.5 ml - peginterferon alfa-2a 180 mcg/0.5 ml

Singapoo - Kiingereza - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 100 mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

gilead sciences singapore pte. ltd. - tenofovir disoproxil 245mg eqv tenofovir disoproxil fumarate - tablet, film coated - 300mg/ tablet - tenofovir disoproxil 245mg eqv tenofovir disoproxil fumarate 300 mg

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp & dohme b.v. - interferon alfa-2b - carcinoid tumor; leukemia, hairy cell; lymphoma, follicular; hepatitis b, chronic; hepatitis c, chronic; leukemia, myelogenous, chronic, bcr-abl positive; melanoma; multiple myeloma - immunostimulants, - chronic hepatitis btreatment of adult patients with chronic hepatitis b associated with evidence of hepatitis-b viral replication (presence of dna of hepatitis-b virus (hbv-dna) and hepatitis-b antigen (hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and / or fibrosis.chronic hepatitis cbefore initiating treatment with introna, consideration should be given to the results from clinical trials comparing introna with pegylated interferon.adult patientsintrona is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for hepatitis-c virus-rna (hcv-rna).the best way to use introna in this indication is in combination with ribavirin.children three years of age and older and adolescentsintrona is indicated, in a combination regimen with ribavirin, for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that resulted in reduced final adult height in some patients.the decision to treat should be made on a case-by-case basis.hairy-cell leukaemiatreatment of patients with hairy cell leukaemia.chronic myelogenous leukaemiamonotherapytreatment of adult patients with philadelphia-chromosome- or bcr/abl-translocation-positive chronic myelogenous leukaemia.clinical experience indicates that a haematological and cytogenetic major / minor response is obtainable in the majority of patients treated. a major cytogenetic response is defined by < 34 % ph+ leukaemic cells in the bone marrow, whereas a minor response is ≥ 34 %, but < 90 % ph+ cells in the marrow.combination therapythe combination of interferon alfa-2b and cytarabine (ara-c) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.multiple myelomaas maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.follicular lymphomatreatment of high-tumour-burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a chop-like regimen. high tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°c for more than eight days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.carcinoid tumourtreatment of carcinoid tumours with lymph node or liver metastases and with 'carcinoid syndrome'.malignant melanomaas adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence, e.g. patients with primary or recurrent (clinical or pathological) lymph-node.

Kanada - Kiingereza - Health Canada

boehringer ingelheim (canada) ltd ltee - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Kanada - Kiingereza - Health Canada

apotex inc - nevirapine; zidovudine; lamivudine - tablet - 200mg; 300mg; 150mg - nevirapine 200mg; zidovudine 300mg; lamivudine 150mg - nonnucleoside reverse transcriptase inhibitors

Kanada - Kiingereza - Health Canada

auro pharma inc - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors